米国市場銘柄情報

VIR ヴィル・バイオテクノロジー

銘柄追加

8.230
+0.600+7.86%

終値 04/26 16:00 ET

8.220
-0.010-0.12%

市場後 18:34 ET

11.18億時価総額-1793直近PER

ヴィル・バイオテクノロジーに関するコメント

ログインコメントを投稿

QianmengYu

04/19 00:33

I think CFO is actually fired.

$ヴィル・バイオテクノロジー(VIR.US)$ They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.

QianmengYu

02/23 07:26

good earnings but i don’t like

$ヴィル・バイオテクノロジー(VIR.US)$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...

Movers and Shakers

01/29 21:19

コラムToday's Morning Movers and Top Ratings: MSFT, ZI, AAL, HSY and More

Morning Movers
Gapping up
$ズームインフォ・テクノロジーズ(ZI.US)$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$ボーイング(BA.US)$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...

Meltyy

01/03 20:11

Upcoming Ph 2 readouts in Q1 2024…

$セレクタ・バイオサイエンシズ(CLRB.US)$ Phase 2
$リジェネックスバイオ(RGNX.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アイポイント・ファーマシューティカルズ(EYPT.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ディスク・メディシン(IRON.US)$ Phase 2
$アテア・ファーマシューティカルズ(AVIR.US)$ Phase 2
$アラコス(ALLK.US)$ Phase 2...

Moomoo AI

2023/12/21 20:15

The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.

Possible Bearish Signals With Vir Biotechnology Insiders Disposing Stock

Explore moomoo's "Insider Activity" for institutional sentiment

Moomoo AI

2023/12/14 17:37

Adobe's stock fall and FTC probe may hit future results. Pfizer's reduced earnings projection could reshape investor outlook. Vir Biotechnology's austerity measures aim at fiscal stability. Nordson's weak Q1 forecast may impact near-term stocks.

These Stocks Are Moving the Most Today: Adobe, Apple, Pfizer, Vir Biotechnology, Costco, and More -- Barrons.com

SlowndEasyWins

2023/11/04 12:32

$ヴィル・バイオテクノロジー(VIR.US)$ too late to take position moved so fast

QianmengYu

2023/07/21 23:35

bottom confirms

$ヴィル・バイオテクノロジー(VIR.US)$ so stupid action. Already bought too heavy position. can only average down to 25.5.
I have confidence this is a 20 to 30 dollar stock at least.

rational Duck_7524

2023/07/20 22:37

$ヴィル・バイオテクノロジー(VIR.US)$ how long these company product will get govt blessing? if ages, good to still hold or still Best time to buy more?

QianmengYu

2023/07/20 21:56

what kind of bad joke

$ヴィル・バイオテクノロジー(VIR.US)$ Just bought more. and wait for further dump to buy. Seriously, wall street are upset to Vir’s attitude, not science not finance.
This stupid trial is paid by GSK, HHS, BARDA. Let me make it frank, antibody to virus is proved to be low effectiveness and expensive, you have seen that in Covid. Regeneron faced the same issue for many years, unless trial design is tricky. There is an example antibody works as miracle cure. Regn Cov gives 1200mg antibo...

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気